Uganda Laboratory Core C

乌干达实验室核心C

• 批准号: 8899009
• 负责人: Immaculate Lillian Nankya
• 金额: $ 19.93万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8899009
• 关键词: AIDS clinical trial group; AIDS related cancer; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Area; Arts; Attention; Biological Assay; Canada; Cardiovascular system; Cell surface; Certification; Clinical; Clinical Research; Clinical Sciences; Clinical Trials Unit; Collaborations; Color; DNA; DNA Sequence; Development; Doctor of Philosophy; Drug Evaluation; Drug resistance; Flow Cytometry; Funding; Genotype; Goals; Grant; HIV; HIV drug resistance; HIV-1; Hand; Health Professional; Hospitals; Immune; Immunologics; Immunologist; Immunology; Institutional Review Boards; International; International Cooperation; Interview; Investigation; Investments; Joints; K-Series Research Career Programs; Laboratories; Laboratory Research; Leadership; Learning; Logistics; Malignant Neoplasms; Measurement; Modeling; Molecular Immunology; Molecular Virology; Observational Study; Pathogenesis; Patients; Peripheral Blood Mononuclear Cell; Prevention trial; Process; Quinones; RNA; Research; Research Personnel; Research Project Grants; Research Support; Resource Sharing; Running; Sampling; Scientific Advances and Accomplishments; Scientist; Services; Shipping; Ships; Side; Site; Social Environment; Staging; Testing; Training; Translational Research; Tropism; Uganda; United States National Institutes of Health; Universities; Work; base; cytokine; experience; improved; infrastructure development; new technology; next generation; next generation sequencing; novel; programs; response; social science research; virology; working group

Project Summary Core C – Uganda Laboratory Core A centerpiece for our CFAR is our powerful collaborative research efforts in Uganda at the Joint Clinical Research Centre (JCRC) and Makerere University – a 26 year old program that is widely recognized as a model for successful international cooperation and progress. Currently over 200 Ugandan scientists and health care professionals are actively involved in our collaborative programs. Thanks to substantial investments over a 15- year period by our CFAR it is now possible to undertake cutting edge molecular virology and immunology investigations in Uganda without having to ship samples abroad. Under the leadership of Dr. Eric Arts, Core C has transitioned from a sample processing site performing routine PCR in 1998 to becoming an advanced DNA sequencing service (www.cfarlabs.com). With the introduction of more advanced research/clinical assays and laboratory certification by the WHO (TAQAS, VQA), the Uganda laboratory Core has now grown to provide $503,389 of services over the last grant cycle involving the processing of >30,000 clinical samples and assay of >5,000 drug resistance genotypes since 1998. With Dr. Arts' move to Canada the running of the laboratory will transition to the very capable hands of Dr. Nankya, a 2009 Ph.D. graduate from CWRU who has been managing the laboratory for the last seven years and recently received a CFAR International Career Development Award from DAIDS/NIH. To manage the logistics from the US side and to assist in the development of new scientific programs in Uganda, we have appointed Drs. W. Henry Boom, a distinguished immunologist and TB expert who has worked in Uganda since 2000, and Jacek Skowronski, an outstanding HIV virologist, as Core co-Directors. To improve the sharing of resources and to promote new research initiatives, the Uganda-CWRU Research Collaboration (UCRC) Immunology Laboratory will move to the JCRC and administered by the Uganda Laboratory Core C. In parallel with the Virology laboratory, the Immunology Laboratory has evolved from a sample processing (PBMC, DNA and RNA extraction) service to become an advanced immunology laboratory, performing 7-color flow cytometry for cell surface and intracellular cytokines, as well as a wide variety of immunological assays. These infrastructure developments will take the Uganda Laboratory Core to the next level in its technological capabilities and set the stage of introduction of new CFAR programs on reservoir measurements, HIV-TB interactions, HIV-associated malignancies and cardiovascular complications, as described below. The Specific Aims for Core C are:  To provide virologic and immunologic research support for HIV projects in Uganda aimed at advancing the scientific goals of the Working Groups by US and Uganda-based CWRU/UH CFAR investigators.  To introduce new technology and provide training for US and Uganda-based CFAR investigators for HIV research and its complications in Uganda.  Provide support for clinical research building upon the extensive clinical research experience in Uganda by CWRU's TB Research Unit (TBRU) and AIDS Clinical Trials Unit (ACTU) and for social science research by the Center for Social Science Research on AIDS (CeSSRA). In summary, Core C has evolved from a simple service laboratory to an advanced HIV virology research laboratory focused on the emergence of HIV drug resistance and evaluation of HIV clades circulating in Uganda. During this funding cycle we will expand Core C's activities by integrating it with an advanced immunology lab, and by providing clinical and social science research support. These new developments will aid CWRU/UH CFAR investigators and Ugandan trainees to develop new research projects within CFAR's focus areas on HIV immune-pathogenesis, cure initiatives, and AIDS-related malignancies.

项目摘要核心C - 乌干达实验室核心 我们CFAR的核心是我们在联合临床上在乌干达进行的强大合作研究工作 研究中心（JCRC）和Makerere University - 一个26岁的计划，被广泛认为是模型 成功的国际合作与进步。目前有200多名乌干达科学家和医疗保健 专业人士积极参与我们的协作计划。感谢您对15的大量投资 我们的CFAR的年度现在可以进行尖端的分子病毒学和免疫学 在乌干达进行的调查无需在国外运送样品。在埃里克艺术博士的领导下，核心C 从1998年的样品处理站点过渡了常规PCR，成为高级DNA 测序服务（www.cfarlabs.com）。随着更高级的研究/临床测定和 WHO（Taqas，VQA）的实验室认证，乌干达实验室核心现已发展为提供 在上一个赠款周期中，$ 503,389的服务涉及处理> 30,000个临床样本和测定 自1998年以来，> 5,000种耐药性基因型。随着Arts博士搬到加拿大，实验室的运行将 过渡到2009 Ph.D. Nankya博士非常有能力的手。从一直管理的CWRU毕业 过去七年的实验室，最近获得了CFAR国际职业发展奖 来自daids/nih。管理美国方面的物流，并协助发展新科学 在乌干达的计划，我们任命了Drs。 W. Henry Boom，杰出的免疫学家和结核病专家 自2000年以来一直在乌干达工作，而杰出的HIV病毒学家Jacek Skowronski担任核心联合导演。 为了改善资源的共享并促进新的研究计划，乌干达 - 沃尔研究 合作（UCRC）免疫学实验室将搬到JCRC并由乌干达管理 实验室核心C.与病毒学实验室并行，免疫学实验室从 样品处理（PBMC，DNA和RNA提取）服务成为高级免疫学实验室， 对细胞表面和细胞内细胞因子进行7色流式细胞术，以及多种多样 免疫学测定。这些基础设施的发展将使乌干达实验室核心达到一个新的水平 在其技术能力中，并设定了在水库中引入新的CFAR计划的阶段 测量，HIV-TB相互作用，与HIV相关的恶性肿瘤和心血管并发症，如 如下所述。核心C的具体目标是： 为乌干达的艾滋病毒项目提供病毒学和免疫学研究支持，以促进 我们和位于乌干达的CWRU/UH CFAR调查人员的工作组的科学目标。 引入新技术并为艾滋病毒的我们和乌干达的CFAR调查人员提供培训 研究及其在乌干达的并发症。 为乌干达广泛的临床研究经验提供临床研究的支持 CWRU的结核病研究部（TBR）和AIDS临床试验部（ACTU）和社会科学 社会科学研究中心（CESSRA）的研究。 总而言之，Core C已从简单的服务实验室演变为先进的HIV病毒学研究 实验室的重点是艾滋病毒耐药性的出现和对乌干达循环的艾滋病毒进化枝的评估。 在这个融资周期中，我们将通过将Core C的活动与高级免疫学实验室集成到Core C的活动， 并提供临床和社会科学研究支持。这些新的发展将有助于CWRU/UH CFAR的调查人员和乌干达学员将在CFAR的焦点领域开发新的研究项目 免疫性病理发生，治疗倡议和与艾滋病相关的恶性肿瘤。